Report ID: 10325486 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Uveitis Treatment Market is estimated to reach $1,142 million by 2024; growing at a CAGR of 7.5% from 2016 to 2024. Uveitis is a type of inflammatory disease that induces swelling and destroys eye tissues of one or both eyes. The primary causes of uveitis include toxins that penetrate the eye, infections occurred within eye or any other body parts, bruises to eyes, and attack from own immune system (autoimmunity). Symptoms comprises redness of the eye, blurred vision, eye pain, sensitivity to eye (photophobia), and dark and floating spots in the vision (floaters).
Increasing demand for generic drugs, rising R&D budget for innovations in drugs and treatments, and growing occurrence of uveitis diseases are the major factors supporting the growth of the global uveitis treatment market. However, lack of knowledge, high costs of medications, and possibility of side effects could hamper the growth of the market. Additionally, rising awareness among end-users and advancements in of drugs and treatments for uveitis diseases would provide several growth opportunities in coming years.
The global uveitis treatment market is bifurcated into type, treatment type, and geography. The type segment is categorized as posterior uveitis, anterior uveitis, intermediate uveitis, and panuveitis. Treatment type segment is further sub-segmented into immunosuppressive medications, anti-inflammatory medications, and antibiotic/antiviral medications.
Based on geography, global uveitis treatment market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is further bifurcated in U.S., Canada, and Mexico whereas Europe segment consist of UK, Russia, Germany, France, Italy, and others. Asia-Pacific is segmented into India, China, Japan, South Korea, and others while RoW is bifurcated into South America, Middle East, and Africa.
The key market players include Alimera Sciences Inc., Novartis AG (ALCON), AbbVie Inc., Valeant Pharmaceutical International Inc., Santen pharmaceutical Co., Ltd., EyeGate Pharmaceuticals Inc., Allergan Inc., Bausch & Lomb Incorporated., Amdipharm Mercury Company Ltd., and pSivida Corp., among others.
The key takeaways from the report
The report will provide detailed analysis of Uveitis Treatment Market with respect to major segments such as type, and treatment type
The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
An exhaustive regional analysis of Uveitis Treatment Market has been included in the report
Profile of the key players in Uveitis Treatment Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of Uveitis Treatment Market
Type Segment
Posterior Uveitis
Anterior Uveitis
Intermediate Uveitis
Panuveitis
Treatment Type Segment
Immunosuppressive Medications
Anti-Inflammatory Medications
Antibiotic/Antiviral Medications
Geography Segment
North America
U.S.
Canada
Mexico
Europe
UK
Russia
Germany
France
Italy
Others
Asia-Pacific
India
China
Japan
South Korea
Others
RoW
South America
Middle East
Africa
<
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10325486 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
